MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Sponsor: MedImmune LLC
Listed as NCT02549651, this PHASE1 trial focuses on Diffuse Large B-Cell Lymphoma and remains completed. Sponsored by MedImmune LLC, it has been updated 19 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 14 earlier versions
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Apr 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
May 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .